title: [Recombinant human TSH in pediatric thyroid cancer].
abstract: The treatment of pediatric thyroid cancer usually includes thyroid surgery, therapeutic radioactive iodine ablation, and TSH suppression with levotiroxine. Thyroid hormone withdrawal in the usual follow-up of thyroid cancer has adverse effects on patients. Recominant human (Rh) TSH has the advantage of avoiding both hypothyroidism, with a major impact on the patient's quality of life, and the side effects on tumor growth related to the long-lasting TSH increase. Rh TSH has proven to be effective and safe, but the majority of publications are based on adult population. In this report we present our experience with the administration of Rh TSH in the diagnostic evaluation for treatment in a series of four cases of thyroid cancer in children. In all cases we observed clinical benefits without secondary effects. In conclusion Rh TSH is an appropriate treatment option for the disease and represents a valuable alternative to thyroxin withdrawal.
authors.affiliation: Servicio de Endocrinología Pediátrica, Instituto Mexicano del Seguro Social, Monterrey, Nuevo León, México.
authors.forename: Ana
authors.initials: A
authors.lastname: Bahena-García
authors.forename: Cynthia
authors.initials: C
authors.lastname: Saldívar
authors.forename: Pedro
authors.initials: P
authors.lastname: Siller
authors.forename: Sonia
authors.initials: S
authors.lastname: Lorcansky
authors.forename: Fabián
authors.initials: F
authors.lastname: Pitoia
authors.forename: Héctor Eloy
authors.initials: HE
authors.lastname: Tamez-Pérez
mesh_terms: D000293:Adolescent; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D013964:Thyroid Neoplasms / Q000188:drug therapy*; D057073:Thyrotropin Alfa / Q000627:therapeutic use*
chemical_list: D057073:Thyrotropin Alfa